Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
16
|
pubmed:dateCreated |
1996-9-10
|
pubmed:abstractText |
Epidermal growth factor receptor (EGFR) expression by human breast cancer has been shown to predict poor patient outcome, as has amplification of the c-erbB-2 proto-oncogene. We have developed a quantitative immunohistochemical method for measuring protein levels of both receptors and have applied this to a series of 123 breast primaries. We find EGFR expression is substantially lower than normal in nearly all breast cancers (97%). Quantification of p185erbB-2 indicates overexpression in 91% of the tumors. Two separate tumor populations are apparent with levels of c-erbB-2 expression ranging from 0.33 to 19 and 45 to 480 times normal, respectively. Within the lower population, p185erbB-2 expression is inversely related to EGFR expression (rank correlation, P < 0.0005). Using fluorescent in situ hybridization we show that tumors in the latter population have c-erbB-2 amplification and that amplification is restricted to this group. Our findings indicate that significant overexpression of p185erbB-2 occurs in the absence of amplification; these lower levels of expression may have functional significance. Fifty-three patients underwent in vivo bromodeoxyuridine labeling, allowing flow cytometric analysis of tumor cell cycle kinetics. EGFR expression correlates directly to the labeling index (P = 0.011) and indirectly to potential doubling time (P = 0.010), but not to the duration of the S-phase (P = 0.502). Conversely, p185erbB-2 expression does not relate to indices of proliferation. Our results have important implications for the use of both receptor types as therapeutic targets.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
56
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3823-30
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:8706030-Adolescent,
pubmed-meshheading:8706030-Adult,
pubmed-meshheading:8706030-Breast,
pubmed-meshheading:8706030-Breast Neoplasms,
pubmed-meshheading:8706030-Female,
pubmed-meshheading:8706030-Gene Amplification,
pubmed-meshheading:8706030-Genes, erbB-2,
pubmed-meshheading:8706030-Humans,
pubmed-meshheading:8706030-In Situ Hybridization, Fluorescence,
pubmed-meshheading:8706030-Middle Aged,
pubmed-meshheading:8706030-Prognosis,
pubmed-meshheading:8706030-Receptor, Epidermal Growth Factor,
pubmed-meshheading:8706030-Receptor, erbB-2,
pubmed-meshheading:8706030-Receptors, Estrogen
|
pubmed:year |
1996
|
pubmed:articleTitle |
Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer.
|
pubmed:affiliation |
University Department of Surgery, Glasgow Royal Infirmary, Scotland.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|